TNNT2 and amyotrophic lateral sclerosis: cTnT shows a response to tofersen treatment similar to the previously reported effect on NfL in serum and CSF, thus suggesting cTnT may have use as a complementary biomarker for detecting therapeutic effects in ALS patients.